CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 70 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02743819
NCT02743819Phase 2Active
CompareCT.gov

Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody

University of Chicago·interventional·Posted Apr 19, 2016·Updated Jun 10, 2025

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab and Ipilimumab for Melanoma. Active but no longer recruiting, targeting 70 participants across 10 sites.

Detailed Summary

Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as progression-free survival and safety of the combination following anti-PD1/L1 antibody. The study will also provide the opportunity to investigate blood or tumor based factors that may predict response to anti-PD1 antibody in combination with anti-CTLA4.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedApr 19, 2016
Enrollment StartJun 28, 2016
Primary CompletionJun 1, 2022
Study CompletionJun 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 10.2 years ago

Interventions

Pembrolizumabdrug

Pembrolizumab given every 3 weeks (200 mg) by IV infusion.

Ipilimumabdrug

Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.